Prognostic value of the CHAM score in non-small cell lung cancer patients treated with nivolumab


AĞAOĞLU A. B., EKİNCİ F., ŞAHBAZLAR M., ERDOĞAN A. P.

Clinical and Translational Oncology, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1007/s12094-026-04421-6
  • Dergi Adı: Clinical and Translational Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, DIALNET, Health Research Premium Collection (ProQuest)
  • Anahtar Kelimeler: Biomarkers, CHAM score, Immune checkpoint inhibitors, Non-small cell lung cancer, Prognosis
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

Purpose: Reliable prognostic markers are needed to improve risk stratification in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors. We evaluated the prognostic value of the CHAM score, a composite marker integrating systemic inflammation, hematologic parameters, and metastatic burden, in nivolumab-treated NSCLC patients. To our knowledge, its prognostic relevance in this setting has not been previously investigated. Methods: This retrospective cohort study included 91 patients with histologically confirmed NSCLC who received nivolumab between 2020 and 2026. The CHAM score was derived from C-reactive protein, albumin, hemoglobin levels, and metastatic extent. Overall and progression-free survival were analyzed using the Kaplan–Meier method and compared with the log-rank test. Multivariable Cox proportional hazards regression evaluated the prognostic impact of the CHAM score, and receiver operating characteristic curve analysis determined the optimal cut-off. Results: During follow-up, 59 deaths were observed. Patients with a CHAM score ≥ 4 had shorter overall survival than those with a CHAM score < 4, with median survival times of 6.7 and 18.7 months, respectively (log-rank p < 0.001). Progression-free survival was also reduced in the high-risk group, with median values of 2.6 versus 11.2 months (log-rank p < 0.001). In multivariable Cox regression analyses, a high CHAM score remained independently associated with worse overall and progression-free survival (p < 0.05 for both). Receiver operating characteristic analysis identified a CHAM score of 4 as the optimal cut-off. Conclusions: The CHAM score may provide practical prognostic stratification in nivolumab-treated NSCLC patients; however, external validation is required.